More physicians are using AI for clinical search, pushing tech companies to compete on speed, medical sourcing, and trust.

Mega rounds now dominate late-stage digital health dealmaking, with startups attracting capital through scale, proven market fit, and AI value.

Clinicians and staff adopt “shadow AI” tools to move faster, exposing gaps in hospital AI strategy.

AI’s growing clout in healthcare and pharma and candid confessions from drugmaker CEOs dominated the narrative at JPM 2026.

As funding concentrates among fewer companies, smaller players may need to sharpen differentiation.

Its new ChatGPT for Healthcare aims to win over physicians and health systems with HIPAA-safe, evidence-based tools.

Leading healthcare AI startups, including OpenEvidence, Abridge, UpToDate, and Doximity, are rolling out new products and capabilities in the race to compete for physician adoption and investment funding. Companies could gain an advantage by making their products easily integrated into clinicians’ existing workflows, such as their EHRs. Startups should also showcase the outcomes of their technology to influential stakeholders like medical associations to help establish credibility at the clinician level.

The trend: Physicians are ramping up use of AI for pharma-related queries on medications, treatments, and drug interactions. But usage of AI trails search, according to a new Bain & Company. report. The big takeaway: Doctors trust search engines over AI for drug information—for now. The convergence of the two tools via AI Overviews on Google could lead to declining confidence in search results. The winner in securing physician trust could be clinical-specific AI tools like the widely used UptoDate or the emerging OpenEvidence, which brands itself as a ChatGPT for doctors.

The news: Medical AI startup OpenEvidence inked a multi-year agreement with JAMA Network that gives the company access to full-text content from the American Medical Association’s 13 medical journals. Our take: OpenEvidence is competing with Wolters Kluwer’s UptoDate medical information tool, which is used by a few million clinicians worldwide and has recently integrated its own AI search capabilities. One big difference between the products is that OpenEvidence is free for doctors and generates revenue through advertising. Meanwhile, UptoDate does not provide advertising opportunities. We think that OpenEvidence’s internal AI prowess could give it the leg up as long as its in-platform advertising doesn’t turn off doctors too much.